Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 10, 2025Journal of the American Heart AssociationOpen Access

External Validation of a Risk Prediction Model for Atherosclerotic Cardiovascular Diseases in a Large National Health‐Checkup and Claim Database

View Full Paper
Ask AI
Bookmark
Share

Authors

THTakanori HondaYFYoshihiko FurutaAMAkihiro Maezono

Discussion

Loading...

Member takes

Overview

Retrospective cohort study confirms Hisayama model's predictive performance for ASCVD risk, enhancing risk communication.

Key Points

  • The Hisayama ASCVD model exhibited good predictive performance in identifying risk for cardiovascular diseases.
  • During a follow-up of 4.4 years, 3998 out of 420,552 individuals developed atherosclerotic cardiovascular diseases.
  • External validation demonstrated the model's effectiveness with a C-statistic of 0.766 after recalibration for the Japanese population.
  • The model's predictive accuracy was consistent across diverse subgroups, supporting its use in national health screenings.

Cite This Study

Honda et al. (2025) studied this question.

synapsesocial.com/papers/68c23e02b210217d64790504https://doi.org/10.1161/jaha.124.040386
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CHARIOT: Development and Internal Validation of a Cardiovascular Health Assessment and Risk-based Intervention Optimisation Tool2025 · 1 citations
  2. 2Comparison of Short‐ and Long‐Term Cardiovascular Disease Risk Assessment Tools in US Young Adults2025
  3. 3Development and Validation of an Explainable Prediction Model to Assess the Risk of Coronary Artery Disease in Young and Middle-Aged Individuals2025
  4. 4Validation of the American Heart Association Predicting Risk of Cardiovascular Disease Events Equations in Diverse Socioeconomic Groups: The All of Us Cohort2025
  5. 5Independent external validation and head-to-head comparison of guideline-recommended CVD risk prediction models.2026